Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1

Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma

(2016) Lavinia Spain et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

(2016) Junzo Hamanishi et al.   International Journal of Clinical Oncology

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

(2016) Mark J. Selby et al.   PLoS One

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis

(2016) Madison Black et al.   Oncotarget

Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013

(2016) Yuan-Sheng Chen et al.   Human Vaccines & Immunotherapeutics

Novel immunotherapy in the treatment of advanced non-small cell lung cancer

(2016) G. Santabarbara et al.   Expert Review of Clinical Pharmacology

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

Immunotherapeutic approaches to ovarian cancer treatment

(2015) Cariad Chester et al.   Journal for ImmunoTherapy of Cancer

Multi-fragment site-directed mutagenic overlap extension polymerase chain reaction as a competitive alternative to the enzymatic assembly method

(2013) Marcus Wäneskog et al.   ANALYTICAL BIOCHEMISTRY

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

(2013) Jedd D. Wolchok et al.   Annals of the New York Academy of Sciences

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

(2013) Xiaoxiao Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

(2013) Li Shi et al.   Journal of Hematology & Oncology

PD-1 as a potential target in cancer therapy

(2013) David F. McDermott et al.   Cancer Medicine

Tumor Immunotherapy Directed at PD-1

(2012) Antoni Ribas   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

IL-22R, IL-10R2, and IL-22BP Binding Sites Are Topologically Juxtaposed on Adjacent and Overlapping Surfaces of IL-22

(2008) Paul W. Wu et al.   JOURNAL OF MOLECULAR BIOLOGY

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

(2008) D. Y.-w. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA